Changchun High-tech: Subsidiary GenSci's application for registration and clinical trial of 144 domestically produced drugs has been accepted.

Changchun High-tech announced that its holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. has received the "Acceptance Notice" issued by the National Medical Products Administration for the domestic production drug registration clinical trial application of GenSci 144 tablets. GenSci 144 tablets is an orally administered small molecule SLC6A19 inhibitor independently developed by Jinsai Pharmaceutical, classified as Class 1 chemical drug, intended for the treatment of phenylketonuria.